Strategic Partnerships Levitabio has recent collaboration activity with Cytiva and Planet Innovation to advance LeviCell capabilities, signaling an openness to co-developed solutions and channel partnerships that can be leveraged to expand market reach and accelerate adoption in academia and industry.

High Throughput Growth The introduction of LeviCell EOS with higher throughput for cell isolation suggests a focus on scalable workflows, creating opportunities to target larger research labs, core facilities, and contract research organizations seeking efficient sample processing.

Immune Profiling Upsell Launch of LeviSelect cell depletion and enrichment kits positions LevitasBio in the immunology segment, presenting cross-sell opportunities to immunology researchers and clinics requiring advanced sample prep and targeted cell enrichment.

End-to-End Value As an end-to-end sample processing and analysis provider, LevitasBio can cross-sell integrated LeviCell systems with complementary services and software (e.g., Salesforce-driven workflows, CRM-enabled support) to convert larger lab portfolios and boost lifecycle value.

Funding and Scale Signals Recent Series C funding and leadership hires indicate financial momentum and strategic growth; leverage this narrative to engage strategic customers and healthcare/academic institutions planning long-term capital investments in cellular analysis infrastructure.